|
|
Co diagnostics Inc (NASDAQ: CODX) |
|
Price: $0.4166
$-0.05 
-10.022%
|
| Day's High:
| $0.4493
| Week Perf:
| -14.81 %
|
| Day's Low: |
$ 0.40 |
30 Day Perf: |
-28.09 % |
| Volume (M): |
197 |
52 Wk High: |
$ 2.23 |
| Volume (M$): |
$ 82 |
52 Wk Avg: |
$1.06 |
| Open: |
$0.44 |
52 Wk Low: |
$0.40 |
|
|
| Market Capitalization (Millions $) |
13 |
| Shares
Outstanding (Millions) |
30 |
| Employees |
70 |
| Revenues (TTM) (Millions $) |
7 |
| Net Income (TTM) (Millions $) |
-41 |
| Cash Flow (TTM) (Millions $) |
1 |
| Capital Exp. (TTM) (Millions $) |
1 |
Co Diagnostics Inc
Co-Diagnostics Inc. is a molecular diagnostics company that develops and commercializes innovative testing solutions for a variety of industries. The company's core focus is on developing and manufacturing polymerase chain reaction (PCR) diagnostics for infectious diseases, liquid biopsy, and other molecular testing markets. Co-Diagnostics uses its proprietary technology to create high-quality and affordable tests that offer fast and accurate results. Their tests are designed to detect a wide range of pathogens and genetic markers, enabling early diagnosis and effective treatment. The company aims to provide reliable testing solutions that contribute to improved patient outcomes and public health.
Company Address: 2401 S. Foothill Drive Salt Lake City 84109 UT
Company Phone Number: 438-1036 Stock Exchange / Ticker: NASDAQ CODX
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Products & Services
Published Fri, Apr 12 2024 1:30 PM UTC
Reflecting the biotech industry s rapid growth in Utah, Co-Diagnostics, Inc., a prominent molecular diagnostics company, has unveiled a brand new manufacturing facility in Salt Lake City. On April 12, 2024, the organization celebrated this significant milestone with a grand ribbon-cutting event. The inauguration drew the attendance of several dignitaries, including Mayor Woo...
|
| Co Diagnostics Inc
Co Diagnostics Inc Announces Strong Revenue Growth and Declining Inventories
Salt Lake City, March 14, 2024 - Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company, has reported its financial results for the full year ended December 31, 2023. The company's revenue for the fourth quarter of 2023 showed a remarkable growth of 140.476% year on year, amounting to $3.37 million. However, they experienced a loss of $-0.50 per share during this period.
In comparison to other companies in the Medical Equipment & Supplies sector, Co Diagnostics Inc exhibited higher revenue growth. While the overall sector saw a revenue growth of 6.78% in the fourth quarter of 2023 relative to the same period a year ago, Co Diagnostics Inc surpassed this with its substantial increase.
|
| Co Diagnostics Inc
Co Diagnostics Inc, a prominent player in the medical diagnostics industry, recently reported its most recent financial results, which have been described as disastrous. The company experienced a significant decline in revenue and an expansion of net deficit per share compared to the previous fiscal period. The financial figures indicate a challenging road ahead for Co Diagnostics Inc.
1. Declining Revenue and Expanding Net Deficit:
In the most recent fiscal period, Co Diagnostics Inc witnessed a sharp decline in revenue by -51.769% to $2.46 million. This decline is concerning, as it indicates a potential decrease in customer demand for the company's products and services. Furthermore, the net deficit per share expanded to $-0.20, a significant increase compared to the same quarter a year ago, highlighting the company's deteriorating financial performance.
|
| Co Diagnostics Inc
Co Diagnostics Inc (CODX) recently released its financial results for the time-frame ending June 30, 2023, and unfortunately, the figures were quite disastrous. The company reported a significant decline in revenue, which faded by a staggering -96.062%, amounting to a mere $0.20 million. This represents a huge setback compared to the comparable reporting period in the previous year. Additionally, the net loss per share widened to $-0.31, further confirming the challenging financial situation faced by the company.
In contrast to Co Diagnostics Inc's dismal performance, the rest of the Medical Equipment & Supplies industry recorded a growth in revenue during the second quarter of 2023. This further highlights the difficulties faced specifically by Co Diagnostics Inc. The revenue tumbled by -67.14%, falling from $0.60 million to its current level. Furthermore, the company reported a net loss of $-8.919 million for the April to June 30, 2023 financial interval. This represents a significant increase from the net loss of $-2.686 million in the same period a year ago.
|
| Co Diagnostics Inc
Co Diagnostics Inc, an innovative molecular diagnostics company, recently announced its financial span ending March 31, 2023. While the results seem disastrous at first glance, those who understand the path of innovation and the life cycle of innovative companies can see the bright future ahead.
According to the report, the company's revenue faded by a staggering 97.348%, dropping to $0.60 million. The shortfall per share extended to $-0.20, indicating a significant decline from the comparable reporting period a year prior. However, these results are not surprising for a company that invests heavily in research and development to push the boundaries of healthcare solutions.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.38 $ |
| Revenues (TTM) |
0.23 $
|
| Cash Flow (TTM) |
0.02 $ |
| Cash |
1.24 $
|
| Book Value |
2.09 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.38 $
|
| Revenues (TTM) |
0.23 $ |
| Cash Flow (TTM) |
0.02 $ |
| Cash |
1.24 $
|
| Book Value |
2.09 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| UNITED STATES |
|
 87.97 % |
of total Revenue |
| UNITED STATES Product |
|
20.24 % |
of total Revenue |
| UNITED STATES Grant |
|
67.73 % |
of total Revenue |
| Rest of World |
|
12.03 % |
of total Revenue |
| Rest of World Product |
|
12.03 % |
of total Revenue |
|
|
0.1%